bg content top pipeline

Molecules Currently in Development and a Licenseable Delivery Vehicle

The Pipeline

RDD chart 121118

RDD recently completed a successful Phase 2a study of RDD 0315 in fecal incontinence, which reached the primary endpoint (lowered frequency of incontinence events). There are no approved therapies for this indication.

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

 

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2018, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top